netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US

ProAxsis awarded a Significant Innovate UK Grant

Jul 24, 2017
-
News, ProAxsis, RNS Announcements

London, UK – July 24th 2017 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces an update for its portfolio company, ProAxsis.

Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited has now gained further support for its ProteaseTag® technology through a project co-funded by the UK’s innovation agency, Innovate UK. ProAxsis has been awarded a grant to support its project titled: “Development of technology to support the advance of new protease therapeutics.” The project will be conducted at the company’s purpose-built laboratory facilities at Catalyst Inc., in Belfast. The Innovate UK grant will commit financial resources of £57,390, representing 60% of the total expected cost of the project.

Commenting on the news, Francois Martelet, Chief Executive Officer of Netscientific and Chairman of ProAxsis said: “We are very excited to announce that ProAxsis has been awarded this grant from the prestigious Innovate UK agency. The award represents external validation of the ProteaseTag® technology and will enable ProAxsis to generate further clinical data, helping ProAxsis advance towards near-term value inflection and commercialisation.”

The full text of the announcement from ProAxsis can be found below.

 

#  #  #

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO
Tel: +44 (0)20 3514 1800
 

Consilium Strategic Communications

Mary-Jane Elliott Jessica Hodgson /

Chris Welsh / Laura Thornton

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison
Tel: +44 (0) 20 7710 7600
 

 

ProAxsis gains further support from Innovate UK

Date: July 24th, 2017

Following its previous success in the BioMedical Catalyst competition, ProAxsis Limited (www.proaxsis.com) has now gained further support for its ProteaseTag® technology, via a project co-funded by the UK’s innovation agency, Innovate UK.  The project, entitled “Development of technology to support the advance of new protease therapeutics”, has been awarded a grant in the Innovation in Health and Life Sciences Round 1 competition.

A number of pharmaceutical companies are currently developing inhibitors against protease targets, such as neutrophil elastase, as treatments of respiratory diseases including bronchiectasis, COPD and cystic fibrosis.  ProAxsis has previously developed a laboratory-based immunoassay and a rapid point-of-care test for neutrophil elastase, utilising its ProteaseTag® technology, which such companies can benefit from.  However, ProAxsis continues to seek to advance the sensitivity of its technology to maximise the range of biological samples it can be used with, and thereby improve the chances of success for these potentially important new therapeutics.

Speaking about the news, Dr David Ribeiro, CEO of ProAxsis, said: “Innovate UK programmes are always hugely competitive so we’re delighted that our project has been selected and are extremely grateful to Innovate UK for their support.  The development of suitable companion diagnostic tests is an essential part of the drug development process.”

The project will commence in July 2017, and will be conducted at the company’s purpose-built laboratory facilities at Catalyst Inc., in Belfast.

Any queries concerning ProAxsis’ Immunoassays for measuring active neutrophil elastase and active plasmin, or any other aspects of the company’s proprietary ProteaseTag® technology, can be directed to info@proaxsis.com.

Innovate UK is the UK’s innovation agency.  It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy.  For further information, please visit www.innovateuk.gov.uk

 

About NetScientific:

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

About ProAxsis Limited:

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease. Its first commercialised immunoassay measures neutrophil elastase, a leading indicator of infection and inflammation in patients with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis, and an important drug target. The rapid and easy-to-use tests being developed by ProAxsis incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.

ProAxsis is part of the NetScientific Group and is one of the Group’s core portfolio companies.  The company is also supported by QUBIS, the commercialisation arm of Queens University. For more information, please visit the website at www.proaxsis.com

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
ProAxsis is awarded a European CE Mark for their NEATstik® point-of-care lung inflammation monitoring test
NEXT POST →
PDS Biotechnology Announces Clinical Collaboration with Merck & Co., Inc.

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
Copyright
Terms of Use
ProAxsis awarded a Significant Innovate UK Grant - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT